2026-08-29T19:28:12Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/234402024-11-28T20:17:15Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Torrens-Mas, Margalida
author
Perelló-Reus, Catalina M
author
Trias-Ferrer, Neus
author
Ibargüen-González, Lesly
author
Crespí, Catalina
author
Galmes-Panades, Aina Maria
author
Navas-Enamorado, Cayetano
author
Sanchez-Polo, Andrés
author
Pierola Lopetegui, Javier
author
Masmiquel, Lluis
author
Socias, Lorenzo
author
Barceló, Carles
author
Gonzalez-Freire, Marta
2024-10-04T13:22:51Z
2024-10-04T13:22:51Z
2022-07-22
Torrens-Mas M, Perelló-Reus CM, Trias-Ferrer N, Ibargüen- González L, Crespí C, Galmes-Panades AM, et al. GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility. Front Cell Infect Microbiol. 2022 Jul 22;12:942951.
10.3389/fcimb.2022.942951
2235-2988
Frontiers in cellular and infection microbiology
http://hdl.handle.net/20.500.13003/18040
35937703
L2018441801
2-s2.0-85135551051
https://hdl.handle.net/20.500.12105/23440
837144000001
Coronavirus disease 19 (COVID-19) is a persistent global pandemic with a very heterogeneous disease presentation ranging from a mild disease to dismal prognosis. Early detection of sensitivity and severity of COVID-19 is essential for the development of new treatments. In the present study, we measured the levels of circulating growth differentiation factor 15 (GDF15) and angiotensin-converting enzyme 2 (ACE2) in plasma of severity-stratified COVID-19 patients and uninfected control patients and characterized the in vitro effects and cohort frequency of ACE2 SNPs. Our results show that while circulating GDF15 and ACE2 stratify COVID-19 patients according to disease severity, ACE2 missense SNPs constitute a risk factor linked to infection susceptibility.
eng
GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility
research article